Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 9 | 2020 | 201 | 1.260 |
Why?
|
| Anthracyclines | 4 | 2018 | 62 | 0.450 |
Why?
|
| Bone Marrow | 2 | 2018 | 70 | 0.440 |
Why?
|
| Lysophospholipase | 1 | 2012 | 5 | 0.420 |
Why?
|
| Glycoproteins | 1 | 2012 | 45 | 0.410 |
Why?
|
| Heart Ventricles | 3 | 2018 | 135 | 0.390 |
Why?
|
| Stroke Volume | 4 | 2018 | 348 | 0.360 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 390 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 458 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2018 | 170 | 0.280 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2018 | 74 | 0.260 |
Why?
|
| Ventricular Function, Left | 3 | 2017 | 245 | 0.260 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 35 | 0.240 |
Why?
|
| Aged | 13 | 2020 | 10301 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 608 | 0.180 |
Why?
|
| Sulfides | 2 | 2018 | 26 | 0.160 |
Why?
|
| Caprylates | 2 | 2018 | 27 | 0.160 |
Why?
|
| Female | 15 | 2020 | 19959 | 0.160 |
Why?
|
| Middle Aged | 13 | 2020 | 11817 | 0.160 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2020 | 2282 | 0.150 |
Why?
|
| Salvage Therapy | 2 | 2015 | 134 | 0.150 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 765 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2017 | 110 | 0.140 |
Why?
|
| Leukemia | 2 | 2014 | 40 | 0.140 |
Why?
|
| Biopsy | 2 | 2018 | 259 | 0.130 |
Why?
|
| Depression | 2 | 2016 | 444 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 257 | 0.130 |
Why?
|
| Cognition | 2 | 2016 | 555 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.120 |
Why?
|
| Male | 13 | 2020 | 19165 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 94 | 0.120 |
Why?
|
| Humans | 15 | 2020 | 32005 | 0.120 |
Why?
|
| Azacitidine | 1 | 2013 | 28 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 3990 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 35 | 0.110 |
Why?
|
| Crystallization | 1 | 2012 | 17 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 246 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 141 | 0.100 |
Why?
|
| Adult | 8 | 2018 | 9345 | 0.100 |
Why?
|
| Heart Failure | 1 | 2018 | 639 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1328 | 0.090 |
Why?
|
| Neoplasms | 1 | 2017 | 726 | 0.090 |
Why?
|
| Aorta | 1 | 2009 | 126 | 0.080 |
Why?
|
| Hospitalization | 1 | 2011 | 470 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3306 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 2018 | 19 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 876 | 0.070 |
Why?
|
| Comorbidity | 3 | 2013 | 566 | 0.070 |
Why?
|
| Cytarabine | 2 | 2018 | 55 | 0.070 |
Why?
|
| Recurrence | 2 | 2018 | 263 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 2149 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 877 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1128 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 447 | 0.060 |
Why?
|
| Mitochondria | 2 | 2018 | 187 | 0.060 |
Why?
|
| Remission Induction | 2 | 2015 | 84 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 276 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2636 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3509 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 317 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 41 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 104 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 154 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2017 | 43 | 0.040 |
Why?
|
| Cell Line | 1 | 2018 | 435 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 96 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 103 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 92 | 0.030 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 117 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 188 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 151 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 163 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 3876 | 0.030 |
Why?
|
| Edema, Cardiac | 1 | 2014 | 13 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 219 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 483 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 14 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 55 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 163 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 22 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 98 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 66 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 63 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 148 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 767 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 726 | 0.030 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 2484 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 753 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2265 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 684 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 293 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 325 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 240 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1188 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 918 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1497 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 898 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 946 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1817 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 1514 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 7541 | 0.020 |
Why?
|